EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lipid nanoparticle–based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways

Narinderjit Singh Sawaran Singh, Ibrahim Saeed Gataa, Luma Hussain Saleh, Subbulakshmi Ganesan, V Kavitha, Laxmidhar Maharana, Renu Sharma, Mutabar Latipova, Nazira Madatova, Doniyor Jumanazarov, Aseel Smerat

Archives of Microbiology · 2026-01 · 208 (1)

DOI: 10.1007/s00203-025-04596-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Microbiology, online erschienen am 12.12.2025. Verfasst von Narinderjit Singh Sawaran Singh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Data Science and Information Technology, INTI International University, Persiaran Perdana BBN, Putra Nilai, 71800, Nilai, Malaysia. narind…. Hauptthemen laut MEDLINE: AIDS Vaccines, HIV Infections, Nanoparticles, RNA, Messenger. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 303 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing an effective HIV vaccine remains a major challenge in modern medicine. The majority of HIV transmissions occur across mucosal surfaces, yet the mucosal immune protection provided by current systemic vaccination strategies is limited. However, the potential of lipid nanoparticle (LNP)-based messenger RNA (mRNA) vaccines to revolutionize HIV prevention is a source of hope and optimism. Additionally, circular RNA (circRNA) represents an emergent platform that may offer potential for mucosal HIV vaccine development. This review examines the relationship between mRNA-LNP formulation science and mucosal immunology, with a focus on how adjuvant design, device engineering, and delivery methods interact to influence protective outcomes. We summarize the most recent research on mucosal delivery methods, including nasal, vaginal, rectal, and pulmonary routes, as well as formulation techniques to overcome obstacles such as mucus penetration, enzymatic breakdown, and epithelial absorption. We also examine how mRNA design (including nucleoside modification status) and prime-boost regimens influence the desired immunological outcomes, such as the induction of mucosal secretory IgA (SIgA), tissue-resident memory T cells (TRM), and a balanced systemic-local immune response. The microbiome and mucosal inflammation are examined in relation to safety, tolerability, and regulatory considerations. We stress the importance of future research priorities, including integrated prime-boost schedules, adjuvant tuning, and early human trials, to engage the audience and commit to the advancement of HIV prevention. We also highlight translational roadblocks, such as the lack of standardized mucosal assays, limited preclinical challenge data, and manufacturing challenges. When combined, mucosal delivery of mRNA vaccines made with LNP presents a promising strategy for preventing HIV by focusing immune responses at viral entry points.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AIDS VaccinesHIV InfectionsNanoparticlesRNA, MessengerLipidsHumansImmunity, MucosalAnimalsAdjuvants, ImmunologicMucous MembraneAdministration, MucosalLiposomes

Stichwörter der Autor:innen

HIVLipid nanoparticlesMucosal deliveryMucosal immunityVaccine formulationmRNA vaccine

Substanzen

AIDS VaccinesRNA, MessengerLipid NanoparticlesLipidsAdjuvants, ImmunologicLiposomes

Autor:innen und Institutionen

  • Faculty of Data Science and Information Technology, INTI International University, Persiaran Perdana BBN, Putra Nilai, 71800, Nilai, Malaysia. narinderjits.sawaran@newinti.edu.my.
  • Warith Al-Anbiyaa University, Karbala, 56001, Iraq.
  • Department of Anesthesia Techniques, Health and Medical Techniques College, Alnoor University, Mosul, Iraq.
  • Department of Chemistry and Biochemistry, JAIN (Deemed-to-Be University), Bangalore, Karnataka, India.
  • Department of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
  • Department of Pharmaceutical Sciences, Siksha 'O' Anusandhan (Deemed to Be University), Bhubaneswar, Odisha, India.

Zitieren

APA

Sawaran Singh, N. S., Gataa, I. S., Saleh, L. H., Ganesan, S., Kavitha, V., Maharana, L., Sharma, R., Latipova, M., Madatova, N., Jumanazarov, D., & Smerat, A. (2026). Lipid nanoparticle–based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways. Archives of Microbiology, 208(1). https://doi.org/10.1007/s00203-025-04596-6

Vancouver

Sawaran Singh NS, Gataa IS, Saleh LH, Ganesan S, Kavitha V, Maharana L, et al. Lipid nanoparticle–based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways. Archives of Microbiology. 2026;208(1). doi:10.1007/s00203-025-04596-6

BibTeX
@article{SawaranSingh2026,
  author = {Sawaran Singh, Narinderjit Singh and Gataa, Ibrahim Saeed and Saleh, Luma Hussain and Ganesan, Subbulakshmi and Kavitha, V and Maharana, Laxmidhar and Sharma, Renu and Latipova, Mutabar and Madatova, Nazira and Jumanazarov, Doniyor and Smerat, Aseel},
  title = {Lipid nanoparticle–based mRNA platforms for mucosal HIV vaccines: formulation advances, immune mechanisms, and translational pathways},
  journal = {Archives of Microbiology},
  year = {2026},
  volume = {208},
  number = {1},
  doi = {10.1007/s00203-025-04596-6}
}
Kostenlos starten →